Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Aomori
Clinical trial register · Japan

Clinical Trials in Aomori, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2516 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2516
Studies in scope
all four open statuses
1285
Recruiting now
open to new participants
352
Lead sponsors
across recruiting studies
Top sites
Fukuoka 557 Nagoya 513 Sapporo 400 Tokyo 375 Osaka 354
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 GlaxoSmithKline5 Novo Nordisk A/S4 Celgene3 Hoffmann-La Roche2 Bristol-Myers Squibb2 Daiichi Sankyo2 Gilead Sciences1 Eisai Inc.1 Ono Pharmaceutical Co., Ltd.1 Sumitomo Pharma America, Inc.1 Avidity Biosciences, Inc.1 Biogen1 AbbVie1 BioNTech SE1 argenx1
Site location
Fukuoka557 Nagoya513 Sapporo400 Tokyo375 Osaka354 Chiba328 Kashiwa317 Yokohama272 Kobe239 Kyoto231 Hiroshima224 Sendai207 Chūōku202 Matsuyama172 Bunkyō City171 Kanazawa149 Kumamoto147 Okayama133 Kashiwa-shi132 Niigata120 Fukushima114 Kagoshima107 Kanagawa105 Aichi104 Gifu103 Show all 938
All 938 locations
Target enrolment
to

Trials with a site in Aomori

33 of 2516 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Aomori, Chikushino-shi, Chūōku, Fukui-shi, Fukushima, Higashiibaraki-gun, Higashiohmi-shi, Iwakuni-shi
2026-08-24
Recruiting
AstraZeneca
Phase 2
320
Aomori, Bunkyō City, Fukuoka, Hamamatsu, Hitachi-Naka, Iizuka-shi, Kawachinagano-shi, Matsuyama
2025-12-15
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Aomori, Bunkyō City, Chūōku, Hiroshima, Izunokuni, Osaka, Saga, Shimotsuke
2025-08-22
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
Aomori, Osaka, Tokyo
2025-06-26
Recruiting
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
NCT06803823Agitation Associated With Alzheimer's Disease Dementia
Ono Pharmaceutical Co., Ltd.
Phase 2
90
Aichi, Akita, Aomori, Fukui, Fukuoka, Gunma, Hiroshima, Hokkaido
2025-05-01
Recruiting
Novo Nordisk A/S
Observational
630
Koriyama-shi, Fukushima, Oita-shi, Oita,, Kumamoto, Aichi, Aomori, Chiba, Chitose, Hokkaido, Ehime
2025-04-15
Recruiting
Hoffmann-La Roche
Phase 3
600
Asahikawa-shi, Takamatsu, Sendai, Aichi, Aomori, Chiba, Chikushino-shi, Ehime
2025-03-17
Recruiting
BioNTech SE
Phase 2/3
1,580
Ageo, Akashi, Aomori, Bunkyō City, Chūōku, Funabashi, Himeji, Hiroshima
2025-01-07
Active, closed
Daiichi Sankyo
Phase 3
700
Akita, Aomori, Bunkyō City, Chiba, Fukuoka, Fukuyama, Gifu, Hamamatsu
2024-11-19
By invitation
Novo Nordisk A/S
Observational
23
Toshima City, Aomori, Fukuoka, Hokkaido, Kagoshima, Kanagawa, Kitakyusyu-shi, Fukuoka, Okinawa
2024-08-08
Active, closed
Novo Nordisk A/S
Observational
1,071
Tokyo, Kumamoto, Aichi, Akita, Akita-shi, Akita, Aomori, Bunkyo-ku, Tokyo, Chiba
2024-06-11
Recruiting
GlaxoSmithKline
Phase 3
864
Aichi, Aomori, Chiba, Ehime, Fukuoka, Gunma, Hokkaido, Hyōgo
2024-03-21
By invitation
Novo Nordisk A/S
Observational
200
Aichi, Aomori, Asahikawa, Hokkaido, Beppu-shi, Oita-ken, Chiba, Fukuoka, Fukuoka-shi, Fukuoka-ken, Fukuoka-shi, Fukuoka
2023-10-04
Active, closed
Hoffmann-La Roche
Phase 3
459
Aichi, Aomori, Chiba, Chūō, Ehime, Fukuoka, Hiroshima, Hokkaido
2023-08-08
Recruiting
GlaxoSmithKline
Phase 1/2
123
Aomori, Chiba, Kanagawa, Osaka, Tokyo, Yamagata
2023-06-14
Active, closed
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
NCT05729711Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
AstraZeneca
Observational
416
Aichi, Akita, Aomori, Chiba, Fukui, Fukuoka, Gifu, Gunma
2023-04-04
Active, closed
Biogen
Phase 2/3
450
Nagoya, Toyoake-shi, Aomori, Urayasu-shi, Yoshida-gun, Kitakyushu-shi, Sapporo, Kakogawa-shi
2022-09-13
Active, closed
GlaxoSmithKline
Phase 3
110
Aomori, Chiba, Gifu, Hyōgo, Miyagi, Tokyo, Wakayama, Yamanashi
2022-09-06
Active, closed
Celgene
Phase 3
939
Matsuyama, Higashi-Ibaraki-gun, Shimotsuga, Nerima-ku, Shinagawa-ku, Chuo-shi, Aomori, Chiba
2022-06-23
Recruiting
AstraZeneca
Observational
300
Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima
2022-06-02
Active, closed
Daiichi Sankyo
Phase 3
740
Aomori, Kashiwa-shi, Matsuyama, Fukuoka, Kurume-shi, Kanazawa, Yokohama, Kumamoto
2022-03-04
Active, closed
Bristol-Myers Squibb
Phase 2
19
Nagoya, Toyoake, Aomori, Kamogawa, Kashiwa-shi, Matsuyama, Yoshida Gun, Fukuoka
2022-01-17
Active, closed
AstraZeneca
Observational
1,620
Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima
2021-12-21
Active, closed
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
NCT05101096Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer
DrugSacituzumab Govitecan
Gilead Sciences
Phase 1/2
135
Aichi, Akita, Aoba-ku, Aomori, Asahi-ku, Bunkyō City, Chiba, Chūōku
2021-10-20
Active, closed
GlaxoSmithKline
Phase 3
24
Aomori, Fukuoka, Himeji, Kamakura, Kitakyushu, Kochi, Matsuyama, Nagoya
2021-07-28
Active, closed
AstraZeneca
Phase 3
1,157
Akashi-shi, Aomori, Bunkyō City, Chiba, Chūōku, Fukushima, Hidaka-shi, Hiroshima
2021-04-26
Active, closed
Celgene
Phase 3
313
Nagasaki, Sayama, Bunkyo-ku, Chūō, Aomori, Bunkyō City, Isehara City, Kanagawa, Kamakura
2021-02-25
Active, closed
Bristol-Myers Squibb
Phase 1/2
31
Suwa, Bunkyo-ku, Chūō, Aomori, Bunkyō City, Fukuoka, Hitachi, Ibaraki, Isehara City, Kanagawa
2020-10-12
Active, closed
AbbVie
Phase 3
330
Nagoya, Toyoake, Aomori, Chiba, Kashiwa-shi, Toon-shi, Fukuoka, Fukushima
2020-08-31
Active, closed
GlaxoSmithKline
Phase 3
494
Aichi, Aomori, Ehime, Fukuoka, Gifu, Gunma, Hyōgo, Kanagawa
2020-05-07
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
240
Aichi, Aomori, Chiba, Fukuoka, Hokkaido, Kamakura, Miyazaki, Okayama
2019-12-16
Active, closed
Celgene
Phase 1/2
466
Matsuyama, Aomori, Hiroshima, Isehara City, Kanagawa, Kamogawa, Kyoto, Nagasaki, Nagoya
2016-10-14
Active, closed
Eisai Inc.
Phase 3
1,069
Aichi, Akita, Aomori, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo
2016-10-13
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-japan/city/aomori

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,516 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies with a site in Aomori.

How many clinical trials are recruiting in Aomori?

11 of the 33 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Aomori), 33 studies
PhaseStudiesRecruitingShare
Phase 316448.5%
Observational7221.2%
Phase 1/25215.2%
Phase 2329.1%
Phase 2/3216.1%

Most active sponsors

Lead sponsors with the most studies (Aomori)
Lead sponsorStudiesRecruiting
AstraZeneca63
GlaxoSmithKline52
Novo Nordisk A/S41
Celgene30
Bristol-Myers Squibb20
Daiichi Sankyo20
Hoffmann-La Roche21
AbbVie10
argenx11
Avidity Biosciences, Inc.10
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.